#USA #Los Angeles #DJS Law Group #ImmunityBio #IBRX

Class Action Lawsuit Against ImmunityBio, Inc.

On April 20, 2026, the DJS Law Group announced that a class action lawsuit has been initiated against ImmunityBio, Inc., a publicly traded biotechnology firm, under the premise that the company has violated securities laws. This suit specifically addresses potential breaches of the Securities Exchange Act of 1934, namely sections 10(b) and 20(a) as well as Rule 10b-5, which are designed to protect investors from false and misleading statements.

Overview of the Case

According to the details provided in the lawsuit, the period for the class action spans from January 19, 2026, to March 24, 2026. During this timeframe, ImmunityBio allegedly made misleading assertions regarding its Anktiva medication, creating a false sense of security among investors. The lawsuit claims that these misleading statements materially inflated the company's stock prices, ultimately resulting in significant financial losses for investors who bought shares during this period.

Key Facts from the Lawsuit

The core issue revolves around ImmunityBio’s public communication that purportedly overstated the effectiveness and capabilities of its Anktiva treatment. The complaint contends that the information disseminated by the company did not align with the actual performance of the product, leading to misleading perceptions in the market. Investors who feel they have been adversely affected by these proclamations are now being urged to come forward.

Next Steps for Affected Investors

The DJS Law Group is urging shareholders who purchased ImmunityBio shares during the specified class period to evaluate their losses and consider joining the lawsuit. Most notably, it is highlighted that one does not need to be the lead plaintiff to seek recovery, thereby making participation accessible for any investor impacted by the misleading information.

With a deadline set for May 26, 2026, investors are encouraged to act quickly. The DJS Law Group possesses a strong reputation for representing large investors, including sophisticated hedge funds and alternative asset managers. Their expertise in handling securities class actions positions them as a reliable ally for shareholders seeking justice in the face of corporate misconduct.

Why Choose DJS Law Group?

DJS Law Group emphasizes a commitment to enhancing investor returns through aggressive representation and comprehensive advocacy. They specialize in navigating the complexities of securities law and corporate governance disputes. Their focus on maintaining the relationship with their clients and addressing their needs underscores their credibility in the legal domain.

The firm recognizes the value of litigation claims for their clients, considering them crucial assets that need diligent management and respect. Therefore, they are dedicated to securing justice and financial recovery for those affected.

Conclusion

As this class action lawsuit progresses, it serves as a critical reminder for investors to remain vigilant about the information provided by publicly traded companies. Misleading statements can have real financial repercussions, and it’s important for investors to know their rights and the avenues available to seek redress. If you believe you have been affected by ImmunityBio’s statements during the defined class period, now is the time to consider your options and reach out to legal counsel for guidance. Join the efforts of DJS Law Group as they advocate for accountability and recovery for harmed investors.